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The immune system generally avoids horror autotoxicus or auto-
immunity, an attack against the body’s own constituents. This
avoidance requires that self-reactive T cells be actively silenced or
tolerized. We propose that dendritic cells (DCs) play a critical role
in establishing tolerance, especially in the periphery, after func-
tioning T cells have been produced in the thymus. In the steady
state, meaning in the absence of acute infection and inflammation,
DCs are in an immature state and not fully differentiated to carry
out their known roles as inducers of immunity. Nevertheless,
immature DCs continuously circulate through tissues and into
lymphoid organs, capturing self antigens as well as innocuous
environmental proteins. Recent experiments have provided direct
evidence that antigen-loaded immature DCs silence T cells either by
deleting them or by expanding regulatory T cells. This capacity of
DCs to induce peripheral tolerance can work in two opposing ways
in the context of infection. In acute infection, a beneficial effect
should occur. The immune system would overcome the risk of
developing autoimmunity and chronic inflammation if, before
infection, tolerance were induced to innocuous environmental
proteins as well as self antigens captured from dying infected cells.
For chronic or persistent pathogens, a second but dire potential
could take place. Continuous presentation of a pathogen by
immature DCs, HIV-1 for example, may lead to tolerance and active
evasion of protective immunity. The function of DCs in defining
immunologic self provides a new focus for the study of autoim-
munity and chronic immune-based diseases.
The experiments of Paul Ehrlich at the turn of the last centuryhelped establish the science of immunology. In addition to
his prescient findings on specific immune receptors (1), Ehrlich
used a collection of stains to identify many types of white blood
cells, including lymphocytes, the mediators of immunity. Ehrli-
ch’s experiments on antibodies led him to conclude that immu-
nity is exclusively directed to foreign materials or antigens;
normally there is no reactivity or tolerance to self. For example,
he found that a goat made antibodies to red blood cells from
other goats but not to its own red blood cells. Thus the body
avoids an immune attack on itself. He states: ‘‘We pointed out
that the organism possesses certain contrivances by means of
which the immunity reaction, so easily produced (induced) by all
kinds of cells, is prevented from acting against the organism’s
own elements and so giving rise to autotoxins . . . so that one
might be justified in speaking of a ‘horror autotoxicus’ of the
organism’’ (p. 253, ref. 2). Actually, autoimmunity does develop
in many diseases, including systemic lupus erythematosus,
multiple sclerosis, rheumatoid arthritis, psoriasis, and juvenile
diabetes.
Ehrlich suggested that self-reactive lymphocytes could be
silenced or tolerized by losing their self-specific receptors (p. 208,
ref. 2), a prediction that has proven correct for antibody-
producing B cells (3, 4). Here we propose that one type of white
cell, the dendritic cell (DC), has major roles in silencing self-
reactive T lymphocytes. These T cells are produced centrally in
the thymus, where some self-reactive T cells are tolerized
through the aegis of thymic DCs and other antigen-presenting
cells (Fig. 1). Then T cells emerge into the periphery to patrol
and defend the body against pathogens. Here evidence will be
outlined that DCs silence peripheral T cells as well (Fig. 1).
Before going over this information, two background topics need
to be considered: the limitations of central thymic tolerance and
the traditional function of DCs in inducing immunity to foreign
antigens especially infections (5, 6).
Central Tolerance
The Importance of Central Tolerance in Preventing Autoimmunity.
So-called central tolerance is the best-known pathway to silenc-
ing self-reactive lymphocytes. Developing B and T cells rear-
range Ig and T cell receptor genes to produce clones of lym-
phocytes with unique antigen receptors. Gene rearrangement is
random, so that both self- and nonself-reactive clones are
produced in the central lymphoid organs, the bone marrow, and
thymus. However, when self antigens are present during devel-
opment, the autoreactive B and T cells or their receptors can be
selectively deleted as envisaged by Burnet (7) and Lederberg (8).
Owen first uncovered experimental evidence for this fundamen-
tal developmental route to tolerance in his studies on cattle (9).
He observed that fraternal twins, although genetically different,
failed to mount immune responses to each other’s cells. This
finding was remarkable in view of Ehrlich’s observations that any
individual reliably formed antibodies to the cells of another
individual. The basis for the tolerance in cattle twins was a
shared placental circulation, whereby the twins became hema-
topoietic chimeras during development. Billingham, Brent, and
Medawar exploited Owen’s finding when they made the dramatic
discovery that an injection of foreign white blood cells into
neonatal mice could induce tolerance to transplantation anti-
gens, especially products of the foreign major histocompatibility
complex (MHC) (10). The underlying mechanisms for central
tolerance of developing lymphocytes were then appreciated once
methods were developed to identify these lymphocytes. It was
noted that self-reactive T and B cells were deleted centrally
(11–14) or, in the case of B cells, their receptors could be edited
and replaced by receptors for foreign antigens (3, 4).
DCs and Central Tolerance. DCs play an important role in the
selfnonself distinction imposed by the thymus. Located almost
entirely in circumscribed medullary regions (15, 16), DCs
present self antigens to developing T cells and delete lympho-
cytes with autoreactivity (17–20) (Fig. 1).
Limitations of Central Tolerance. Despite its effectiveness for some
classes of antigens, central tolerance has major limitations
(Table 1). Self-reactive T and B cells can escape deletion and
editing (21) or, as Nossal vividly summarized, ‘‘The immuno-
logical self exerts its purgative mastery on lymphocytes only to
Abbreviations: DC, dendritic cell; MHC, major histocompatibility complex; TLR, toll-like
receptors; TNF, tumor necrosis factor; IFN, interferon.
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a degree’’ (22). Many self antigens may not access the thymus
(23), whereas others are expressed later in life, after the lym-
phocyte repertoire has been formed (24). Furthermore, the body
is constantly exposed to innocuous nonpathogenic environmen-
tal antigens to which it remains tolerant, e.g., proteins and
commensal organisms within our airways and intestines. The
chance that lymphocyte receptors for foreign antigens crossreact
with self proteins is also substantial (25). These limitations of
central tolerance necessitate effective peripheral silencing mech-
anisms (26, 27). Indeed, T lymphocytes can be tolerized in
peripheral tissues (28). Here we propose that DCs function to
control antigen-specific peripheral tolerance (Fig. 2), which may
seem counterintuitive, because DCs have many critical roles in
inducing immunity. We will propose that the tolerizing function
of DCs occurs in the steady state, i.e., before an acute infection,
and is essential to their subsequent function in generating
antimicrobial immunity.
DC Maturation: The Risk of Autoimmunity and Chronic
Inflammation During the Defense Against Pathogens
DC Maturation as a Control Point for Initiating Immunity. DCs are
specialized to process antigens, presenting them as peptides
bound to MHC products and initiating immunity. However, the
capture of antigens and the initiation of immune responses are
distinct functions carried out by DCs at different stages of
development, termed immature and mature (Fig. 2). These
terms have some imprecision (see Questions), because they
encompass cells found in different organs and pathologic settings
as well as DC subsets and DCs generated in culture by different
methods. Nevertheless, most types of immature DCs are known
to capture antigens, both soluble and particulate, and have a
number of receptors and intracellular compartments appropri-
ate for the task (29). During maturation, additional functions
develop that enhance the ability of DCs to induce immunity (Fig.
2) (30–41). Some changes that take place on maturation and
enhance immunogenicity include: (i) increased formation of
stable MHC–peptide complexes (36, 42–44); (ii) higher expres-
sion of membrane molecules like CD86 and other B7 family
members for T cell binding and activation (45–47); (iii) new
synthesis of cytokines that influence T cell proliferation and
differentiation (48, 49); and (iv) altered production of chemo-
kines and chemokine receptors that intensify movement of DCs
into lymphatic vessels and lymphoid organs (50–53).
Janeway has independently emphasized a theme that parallels
DC maturation (54, 55). He reasoned that a key component to
immunogenicity, distinct from antigen processing, is the capacity
of pathogens to activate antigen-presenting cells through pattern
recognition receptors. These receptors induce expression of
costimulatory functions required for immunity. The changes
associated with pathogen recognition are encompassed by the
events of DC maturation. Yet DC maturation also occurs in the
absence of infection, during such powerful T cell immune
responses as transplantation (56), contact allergy (57), and
autoimmunity (58).
The Risks of DC Maturation. To initiate T cell immunity to patho-
gens, DCs must accomplish two things: process the pathogen to
form MHC–peptide complexes (antigen presentation) and dif-
ferentiate or mature as summarized above. However, maturation
creates a problem with respect to selfnonself discrimination.
Consider influenza infection of the lung as an example: DCs not
only capture the virus but also are likely to be taking up dying
influenza-infected cells (59, 60). Furthermore, DCs capture
airway proteins continuously, even without the provocation of a
pathogenic infection (61, 62) (Fig. 3). As Ehrlich would have
predicted, the development of autoimmunity is the exception,
not the rule, during recovery from respiratory and other infec-
tions. He pointed out: ‘‘During the individual’s life, even under
physiological although especially under pathological conditions,
the absorption of all material of its own body can and must occur
very frequently. The formation of tissue autotoxins would there-
fore constitute a danger threatening the organism more fre-
quently and much more severely than all exogenous injuries’’ (p.
253, ref. 2). Even during the influenza pandemic of World War
I, most infected people recovered without residual chronic
reactivity to their airways or airway proteins. How, then, do DCs
stimulate immunity to influenza but at the same time avoid
Fig. 1. Central and peripheral mechanisms for avoiding horror autotoxicus
via T lymphocytes. In the thymus (central tolerance) and in other parts of the
body (peripheral tolerance), self-reactive T cells can either be eliminated
(deleted) or regulated (suppressed) by other T cells. Several types of antigen-
presenting cells can bring about tolerance as shown by the arrows. DCs play a
pervasive role, particularly for dying cells and innocuous self and environmen-
tal proteins that have to be captured and processed before presentation (as
MHC class I and II–peptide complexes) to antigen receptors on T cells.
Table 1. The limitations of central tolerance in avoiding
horror autotoxicus
Self-reactive lymphocytes escape negative selection.
Certain self antigens may not gain sufficient access to thymic
antigen-presenting cells.
Many self antigens are expressed only after the T cell repertoire has
been formed.
Many innocuous environmental proteins enter the body postnatally.
Lymphocyte receptors for foreign antigens can crossreact with self.
Fig. 2. DC maturation, a control point for regulating tolerance and immu-
nity. Immature DCs capture antigens by several pathways, whereas mature
DCs stimulate T cell immunity, i.e., helper and cytolytic effector lymphocytes
as well as memory. Maturation stimuli act via TLRs (wherein distinct microbial
products act although distinct TLR) and TNF family receptors (such as TNF itself
and CD40L). Maturation leads to several changes, including: the redistribution
of MHC class II molecules and MHC–peptide complexes from within the
endocytic system to the cell surface as diagrammed here, the production of
several cytokines and membrane associated T cell stimulatory molecules, and
the remodeling of expressed chemokine receptors.
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stimulation of T cells reactive to self and innocuous environ-
mental antigens?
A Proposal: Immature DCs in the Steady State Define Immunologic Self
and Tolerize T Cells Peripherally, Avoiding the Risks Associated with
DC Maturation During Infection. We suggest that DCs in the steady
state, before infection or inflammation, critically define immu-
nologic self and prevent the induction of both autoimmunity and
chronic inflammation against environmental proteins (Fig. 3).
According to this theory, proteins captured and processed by
DCs in the steady state are tolerogenic, i.e., the DCs silence the
corresponding antigen-specific T cells. As a result, when the
same proteins are presented during infection, the immune
response is able to focus on the pathogen, not on self or
environmental antigens that are presented along with the patho-
gen (Fig. 3). Reciprocally, chronic inflammatory diseases against
otherwise nonpathogenic antigens would be directed primarily
to proteins that are not presented by DCs in the steady state.
Immature DC Function in the Steady State: Migration and
Uptake of Self and Environmental Proteins
The Distribution, Migration, and Turnover of DCs in the Steady State.
DCs are located at body surfaces, especially the skin (30) and
airways (61, 63), in the interstitial spaces of many organs (64),
lymphoid tissues (65, 66), blood (67), and, importantly, affer-
ent lymphatics (68–71), the conduits between peripheral tis-
sues and immunologically active lymph nodes. DCs can insin-
uate themselves into epithelia (61, 72), possibly after the
interaction of CCR6 receptors on DCs (73) with epithelial
MIP-3CCL20 (74). By expressing important molecular com-
ponents of intercellular junctions, DCs at body surfaces may
even insinuate through tight epithelia, extending their pro-
cesses into the environment to capture proteins without break-
ing the epithelial barrier; this phenomenon can be enhanced by
microbial stimuli (75). In mucosal associated lymphoid tissues,
DCs lie beneath the antigen-transporting epithelia, again in
the perfect niche to capture antigens transported through
epithelial M cells (76).
In the steady state, immature DCs circulate between non-
lymphoid and lymphoid tissues at a rapid rate. At least some,
and perhaps most, peripheral DCs enter afferent lymphatics
and then migrate to the T cell area, where they die, because few
DCs are present in efferent lymphatics that leave the lymph
node (70, 77). In mice, the life span of most DCs in the lung
and lymphoid tissues is 2 days (78–81). DC migration from
epithelial surfaces and deeper tissues to lymphoid organs can
be further increased by applying a contact allergen (68) or by
administering inf lammatory cytokines or microbial products
(82, 83). Another group of DCs, termed plasmacytoid cells (84,
85), enter the lymphoid tissues directly from the blood (86).
Thus, DCs patrol most tissues continuously in the steady state.
They are perfectly positioned to capture self and environmen-
tal antigens and to access the corresponding specific T cells
(reviewed in ref. 87).
DCs Capture Antigens in the Steady State. The proposal under
consideration here is that immature DCs in the steady state are
vital to defining self in the periphery. Appropriately, DCs
efficiently pick up and process proteins, e.g., from the airway (61,
62), blood (88–90), muscle (71), and intestine (91). The exper-
imental approach is to inject the antigen without any other
stimulus or adjuvant, isolate DCs a day later, and then test
whether the DCs can present the antigen to specific T cells in
culture. In every case, DCs show high levels of antigen presen-
tation to specific T cells, whereas other cells exhibit little if any
activity (89). Likewise DCs continually capture particulates,
including dying cells in vivo. DCs that traffic through the liver
and into hepatic lymphatics can pick up latex particles and
colloidal carbon (92), Langerhans cells in skin-draining lymph
nodes contain melanin granules acquired from cells in the skin
(93), and DCs capture intestinal epithelial cells before entry into
the mesenteric lymphatics (94). Thus, the normal process of
cellular turnover in nonlymphoid tissues appears to provide
circulating DCs with a constant supply of self antigens for
processing and presentation (94, 95), an important prerequisite
for peripheral tolerance (96). Together, efficient antigen cap-
ture, rapid turnover, and widespread circulation through tissues
allow DCs to perpetually sample self and environmental
antigens.
Two New Lines of Evidence for Peripheral Tolerance via
Immature DCs
Peripheral T Cell Deletion via Immature DCs. Although antigen
uptake by DCs in the steady state is well documented in vivo
(above), the immunologic consequences have not been pursued.
It turns out that peripheral tolerance can ensue. One mechanism
involves deletion of specific T cells, a consequence that parallels
central or thymic tolerance. A recent experiment, which revealed
this role of DCs in situ, involved the targeting of antigens to DCs
through an adsorptive endocytosis receptor, DEC-205 (97, 98).
This receptor is abundantly expressed on many DCs in the T cell
areas of peripheral lymphoid tissues, i.e., in the ideal place to
present captured antigens to T cells circulating through lym-
phoid organs (99). We chose DEC-205 for targeting antigens to
DCs, because it mediates uptake of bound ligand, and its
cytosolic domain contains an EDE triacidic amino acid targeting
sequence that delivers ligands to MHC class II containing
compartments 30–100 times more effectively than homologous
receptors (100). The proteins delivered by DEC-205 to such
compartments are processed and loaded onto MHC class II
molecules (100). Because natural ligands for DEC-205 are not
yet known, anti-DEC-205 antibodies were engineered to carry
antigenic peptides from a model antigen hen egg lysozyme
(HEL). The anti-DECHEL antibody, in fact, targeted selec-
tively to DCs in situ in the steady state, and when corresponding
TCR transgenic T cells were exposed to these targeted DCs, the
T cells proliferated vigorously at first (98). Within a week,
however, the majority of the responding T cells were deleted, and
the mice became tolerant, unable to be primed by injection of
Fig. 3. Overcoming the risk of autoimmunity and horror autotoxicus inher-
ent to the maturation of DCs on exposure to pathogens. During infection, DCs
mature, e.g., in response to pathogen signals via TLRs (Fig. 2). However, the
maturing DCs will likely be presenting peptides not only from the pathogen
but also from dying self tissue and innocuous environmental proteins. To
overcome this risk, it is proposed that immature DCs induce antigen-specific
peripheral tolerance in the steady state, before DC maturation during inflam-
mation and infection. DCs can do so by deleting naı̈ve T cells or inducing
regulatory T cells. The tolerized T cells can either be self-reactive lymphocytes
that have escaped central tolerance or T cells reactive to innocuous proteins in
the environment.









peptide with the powerful Freund’s adjuvant. This peripheral
tolerance could be converted to immunity if the anti-DEC-205
HEL were given together with a DC maturation stimulus.
In these experiments, the doses of injected protein antigen
were low (1 gm of antibody or 15 ngm of peptide), and the
dose of antigen-specific T cells high (2  106 were tolerized; the
total number of T cells in a mouse is estimated to be 2  108,
of which 2  104 typically respond to any one antigen).
Therefore, through the use of DEC-205 to target DCs in the
steady state, small amounts of an intact protein can lead to either
tolerance or immunity. These results contrast with the prior
literature on peripheral tolerance where much higher doses of
preprocessed peptides (100 gm or more) have been used (101,
102). The tolerance observed after targeting of proteins to DCs
in situ also bears on striking observations that bone marrow-
derived cells—presumably DCs (103)—can mediate either pe-
ripheral deletion (104, 105) or anergy (106, 107) in situ. The
DEC-205 targeting experiments specifically implicate DCs as the
inducers of peripheral tolerance by T cell deletion. This outcome
can be converted to immunity if the DCs additionally receive an
appropriate maturation stimulus.
Induction of Regulatory T Cells by Immature DCs. The induction of
regulatory T cells by DCs is another mechanism for peripheral
tolerance. There may be different types of regulatory or
suppressor T cells, e.g., those formed in the thymus and in the
periphery. Regulatory cells are found as a small fraction
(5%) of the T cells in blood, and they are able to suppress
the responses of other T cells to powerful stimuli (108–112).
Because these regulatory cells dampen the responses of other
effector (helper and killer) lymphocytes, they give rise to
functional tolerance. The regulatory mechanisms are at this
time unclear but, in addition, how are these cells induced in the
first place?
The concept is that immature DCs are responsible for the
formation of peripheral regulatory T cells, which has emerged
during studies with DCs in humans. The approach is to isolate
precursors from blood [either CD34  proliferating progenitors
(113) or CD14  nonproliferating monocytes (39, 40)] and
convert these to DCs ex vivo before reinfusion. The field is still
in its early stages (reviewed in refs. 114 and 115), but one of the
goals is to use DCs as ‘‘nature’s adjuvant’’ to immunize patients
against antigens in their tumors. The ex vivo approach is valuable,
because DCs can be loaded with large arrays of antigens,
including those expressed by tumor cells (116, 117), and because
DC maturation can be regulated.
The initial studies of humans in situ were carried out with
mature DCs and a model MHC (HLA-A2.1) binding influenza
viral peptide. A single injection of peptide-charged DCs rapidly
expanded peptide specific immunity an average of 5-fold (118),
whereas a booster dose enhanced T cell functional affinity 30- to
100-fold (119). In contrast, when immature peptide-pulsed DCs
were injected, influenza-specific CD8  interferon (IFN)-
secreting T cells virtually disappeared from the blood stream; in
their place, peptide-specific IL-10-secreting T cells appeared
(41). At least some regulatory T cells are known to produce high
levels of IL-10 (120, 121). When tested, the peptide-specific T
cells induced by immature DCs were indeed able to suppress the
effector function of IFN-secreting cells (M. V. Dhodapkar and
R.M.S., unpublished work). The induction of regulatory cells was
transient and reversed within 1–3 months, with a return of the
IFN-secreting T cells. These in vivo experiments in humans,
coupled with additional studies in tissue culture (122), demon-
strate the capacity of immature DCs to rapidly induce regulatory
T cells. The latter, it is known, are able to silence effector T cells
including autoaggressive ones in mice (27, 110, 123–127). Pos-
sibly regulatory T cells operate by changing the function of DCs
(128). In any case, the induction of these suppressive T cells
provides another mechanism whereby DCs could induce anti-
gen-specific peripheral tolerance.
In summary, we propose that immature DCs define immuno-
logic self, silencing the T cell repertoire to self and environmen-
tal antigens captured during the steady state. When the DCs
subsequently mature in response to infection, the preexisiting
tolerance nullifies the development of reactivity to innocuous
antigens and focuses the immune response on the pathogen. In
the thymus, DCs delete self-reactive T cell clones, whereas in the
periphery, DCs delete T cells and induce the formation of
regulatory T cells. Our proposal draws on the known migratory
and antigen-capturing activities of immature DCs in the steady
state and is supported by recent evidence that DCs tolerize
in situ.
Questions and Challenges That Arise from This Concept of
Peripheral Tolerance
How Does the Idea that DCs Control Tolerance Differ from Other
Theories? Mechanisms of peripheral tolerance have relied on
what is termed the two-signal notion of acquired immunity
(reviewed in ref. 129). The proposal is that the presentation of
self antigens or ‘‘signal one,’’ in the absence of costimulation, or
‘‘signal two,’’ induces T cell anergy or deletion. However, it is
difficult to tolerize an animal with antigen alone, i.e., by the
injection of intact proteins or even preprocessed peptides (101,
102), possibly because antigens need to be captured in sufficient
amounts by immature DCs in order for tolerance to ensue. There
also is information that antigens on non-DCs are ignored and not
truly tolerogenic (130, 131). In other instances, antigens ex-
pressed by non-DCs are able to tolerize but only after processing
by bone marrow derived cells, possibly DCs (105, 132). The
‘‘signal one’’ theory of tolerance therefore seems to be oversim-
plified and suffers from a dearth of evidence with intact soluble
and cell-associated proteins in vivo.
We are instead proposing that the MHC peptide complexes
produced by antigen processing become effective tolerogens
when presented by DCs in the steady state. Also, the induction
of tolerance by immature DCs likely requires a number of
special features of these cells, not just ‘‘signal one’’. Already
evident are: (i) the efficient capture of antigens, including the
exogenous pathway whereby DCs are specialized to form MHC
class I-peptide complexes from soluble proteins, immune
complexes, and dying cells (reviewed in ref. 29); (ii) the
potential to bind T cells to be tolerized via receptors like
DC-SIGN, a newly recognized lectin that interacts with inter-
cellular adhesion molecule-3 on resting T cells (133); (iii) the
production of IL-10 and possibly other regulatory cytokines
(see below); and (iv) the ability to migrate to positions that
optimizes access to antigens and T cells in situ. Likewise, the
alterations that convert DCs to the immunogenic state are
beginning to be unraveled. On microbial challenge, it is known
that maturing DCs: (i) secrete cytokines like IL-12 that cause
the differentiation of T cells to IFNproducing effectors
(134); (ii) express increased levels of the CD80 and CD86
costimulatory molecules (45, 46), particularly in coclusters
with MHC–peptide complexes (36); and (iii) regulate other
costimulatory B7 family members, e.g., a molecule called
B7-DC is induced (47). Despite progress in this area, there is
a great deal to be learned about the features of DCs that
regulate the balance between T cell immunity and tolerance.
Are There Different Types of Immature DCs? There is not simply one
discrete immature and mature type of DCs. Instead, there is a
differentiation pathway triggered by a spectrum of external
stimuli (microbial products, members of the tumor necrosis
factor (TNF) family, other cytokines, heat shock proteins),
possibly with distinct outcomes. In addition there are subsets of
immature DCs, which can differ in their receptors for antigen
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uptake, the cytokines produced on stimulation, and the micro-
bial products to be recognized (135). Currently, a perplexing
area is the relationship between immature DCs produced in
tissue culture and the tolerizing, DEC-205 positive, DCs within
peripheral lymphoid organs. Immature DCs developing in cul-
ture go through a stage where antigens are captured, but MHC
class II–peptide formation is weak (44). In contrast, the imma-
ture DCs in peripheral lymphoid organs (targeted with our
anti-DEC antibodies, above) efficiently process and present
antigens to induce tolerance (98, 136).
The precise physiologic counterpart of the frequently studied
immature DC, produced with cytokines in culture, is not yet
obvious. It may be the Langerhans cell and its homologues in
other surface epithelia andor the monocyte-derived DCs mi-
grating from tissues after encountering antigen (137) or lym-
phatic endothelial cells (138). Understanding the relationships
between these DCs is important, because different immature
cells may induce peripheral tolerance by distinct mechanisms,
such as deletion and induction of regulatory T cells.
Another key variable may be the capacity of immature DCs
to produce IL-10 or other suppressive cytokines like trans-
forming growth factor . MHC class II bearing, IL-10 pro-
ducing cells can regulate experimental autoimmune enceph-
alomyelitis in mice (139). High amounts of IL-10 are made by
DCs isolated from lung (140) and intestine (141) and by DCs
developing ex vivo from monocytes (142–144). This IL-10 may
lead to tolerance in several ways: IL-10 can itself suppress T
cells (145); IL-10 may be required to differentiate regulatory
T cells (125, 146); or IL-10 can act on DCs to decrease their
function (147, 148) or make them tolerogenic (149). In con-
trast, DCs in the T cell areas of lymphoid tissue are not yet
known to be producing IL-10 in the steady state. These DCs
nonetheless can efficiently form MHC class II–peptide com-
plexes and delete T cells in the steady state (98), but they lack
other features of maturing DCs, such as IL-12 production and
high levels of CD86 and CD40 (150, 151).
What Controls DC Maturation? Microbial signaling through toll-
like receptors (TLRs) is an effective way to mature DCs to
their immunogenic state (150–153). However, DC maturation
can also be induced under sterile circumstances, as in the cases
of transplantation (56) and contact allergy (154). In these
intense T cell-mediated immune responses, the requisite re-
ceptors for DC maturation have yet to be identified. A recent
proposal is that TLRs are engaged by endogenous ligands, such
as heparin sulfates and hyaluronans (155, 156). Many cell types
produce cytokines when signaled through TLRs and the
associated MyD88 adaptor protein (157). However, in DCs
there is an additional MyD88 independent TLR-dependent
pathway that leads to maturation and the capacity to initiate
immunity (158, 159). TNF family members, e.g., CD40L on
mast cells and platelets, and hematopoietin families, e.g.,
granulocyte macrophage–colony-stimulating factor, IL-4, IL-
13, additionally inf luence DC development and maturation.
These non-TLR stimuli may produce DCs with different
functions or, alternatively, they may be required in concert
with TLR signaling for full DC activity. For example, DCs
require both a microbial and a TNF family stimulus to make
large amounts of IL-12, a key cytokine for strong cell-mediated
immunity (160). Increased understanding of DC maturation
should yield new ways to manipulate this critical control point
in immunity and tolerance.
Do Other Antigen-Presenting Cells Contribute to the Induction of
Tolerance? Other cells can contribute to tolerance in important
ways (Fig. 1). Thymic medullary epithelial cells can induce
central tolerance (161–163) (reviewed in ref. 164), possibly to
epithelial and neuroendocrine antigens that they synthesize and
that are not otherwise available to thymic DCs. Thymic cortical
epithelial cells recently have been shown to induce suppressor T
cells (165, 166), which seem related functionally to the peripheral
regulatory T cells induced by immature DCs (reviewed in refs.
126, 127, and 167). Liver sinusoidal endothelial cells also can
silence antigen reactive T cells, perhaps those specific for
intestinal proteins that continually enter the portal circulation
(168). B cells have been implicated in T cell tolerance, but, in the
case of a B cell lymphoma, tolerance is induced only after the B
cells are processed by other bone marrow-derived cells, possibly
DCs (107). At this time, DCs cannot be regarded as exclusive
mediators of tolerance or as exclusive mediators of immunity.
Instead, DCs are specialized and efficient controllers of immu-
nity, particularly when proteins (self, environmental, patho-
genic) must be internalized and processed before presentation to
quiescent peripheral T cells.
Implications
Monitoring and Manipulating Tolerance at the Level of Antigen-
Presenting DCs. Dozens of chronic inf lammatory diseases are
considered to be autoimmune in origin, and several autoan-
tigens are known (169). When initiated, autoimmunity can
selectively destroy tissue targets. For example, in juvenile
diabetes, T cells attack insulin-producing cells in the pancre-
atic islets of Langerhans, and in multiple sclerosis, T cells
attack the glial elements of the central nervous system. Other
chronic inf lammatory diseases may represent a failure of
tolerance mechanisms toward normally innocuous environ-
mental proteins and microorganisms rather than self. Inf lam-
matory bowel disease, for example, may be directed to non-
pathogenic bacteria in the intestine.
We have reasoned (Fig. 3) that the function of DCs in
tolerance is most important for those self and environmental
proteins that can be processed during an infection. Other self
antigens could evade DC-mediated peripheral tolerance because
of a low level of expression in the steady state or poor access to
DCs (105, 132). The antigens that are not efficiently presented
by DCs in the steady state might be good candidates to elicit
autoimmune diseases. If these proteins begin to be processed de
novo under conditions compatible with DC maturation, e.g.,
during an infection when proteases are released by inflammatory
cells or from microbes themselves, the previously ignored self
proteins may be presented by mature DCs and autoimmunity
could ensue (170, 171).
The standard experimental and therapeutic approaches to the
induction of tolerance are to use antigen-nonspecific agents,
which impede the function of all T cells, or T cells responding to
any antigen. As in the case of protective immunity, DC biology
opens up the possibility for antigen-specific monitoring and
manipulation of autoimmunity. Mature DCs might be used
experimentally to identify disease-producing autoantigens, as
recently shown for an autoimmune disease called primary biliary
cirrhosis (172), whereas immature DCs might be used to dampen
the autoimmune response in patients. One implication of our
proposal is that the targeting of antigens to DCs in specific states
of maturation may provide novel strategies for vaccination and
immune therapies (41, 98, 173) (M. V. Dhodapkar and R.M.S.,
unpublished work).
Tolerance Induction by Persistent Pathogens. The most challenging
aspect of DC-induced peripheral tolerance relates to persistent
pathogens, both infectious agents and tumors, which are cap-
tured by DCs. Some persistent infections, like herpes simplex
virus (174), cytomegalovirus (175), and plasmodium falciparum
(176), may inhibit DC maturation and decrease the efficacy of
the host immune response. We would like to propose that an
additional strategy on the part of the pathogen is to actively









induce tolerance by virtue of continuous capture and presenta-
tion by immature DCs.
In the case of HIV, a very large number of virions are
produced continuously in infected individuals (177, 178). Tissue
culture experiments indicate that DCs can drive the replication
of virus in T cells (Fig. 4 Upper) (179, 180). DCs can either
replicate HIV, which then infects T cells in large numbers, or
simply capture and directly transmit HIV to permissive T cells.
During chronic infection, patients are essentially asymptomatic.
Their DCs may well be in an immature or steady state and may
take up virions in sizable quantities. Furthermore, immature
DCs express several HIV receptors, such as CD4, CCR5, and
DC-SIGN (181–184), and support virus replication (182, 185).
HIV may therefore exploit immature DCs in an immunologic
sense and not just a virologic one (Fig. 4 Lower). The virus
becomes a very efficient form of ‘‘self,’’ possibly inducing
regulatory T cells andor deleting HIV reactive T cells from the
repertoire. Other chronic infections may likewise induce regu-
latory T cells (186). However, in the case of HIV, the amount of
antigen and the targeting of virus to receptors on immature DCs
should intensify immune evasion through the induction of tol-
erance. Many serious infections, such as tuberculosis and influ-
enza, can be lethal, but the immune system assists the majority
of infected individuals (90%) in recovering without residual
disease. Yet in HIV infection, the immune system is unable to
defeat the pathogen in the vast majority of people, consistent
with some built-in restraint mechanism such as tolerance. The
theory proposed here may help to explain this ominous property
of the AIDS epidemic.
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